KLRS | tickerfilter.com

Fundamental analysis

34%

Profitability 35%

Dept financing 27%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.09%

1 Month

-2.62%

3 Months

-35.41%

6 Months

29.45%

1 Year

-9.70%

2 Year

700.35%

Key data

Stock price

$6.33

P/E Ratio

N/A

DAY RANGE

$6.20 - $6.62

EPS

-$7.46

52 WEEK RANGE

$2.14 - $11.88

52 WEEK CHANGE

-$2.91

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

22.928 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

01-16-2025

NEXT EARNINGS DATE

N/A

BETA

-0.47

PUBLIC FLOAT

AVERAGE 10 VOLUME

$103,684

AVERAGE 30 VOLUME

$88,277

Company detail

CEO: Diana M. Brainard
Region: US
Website: allovir.com
Employees: 110
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies. The company's lead product is posoleucel, which is an allogenic off the shelf VST therapy. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19.

KLRS - Kalaris Therapeutics Inc.